BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Sponsor
Peking University People's Hospital
Study ID
NCT06794008
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • BCMA-CD19 CAR-T therapy — DRUG
    Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.

Study Details

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Key Dates

Start date
Dec 26, 2024
Status verified
Dec 2024
Primary completion
Dec 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CAR-T treatment in patients with multiple refractory autoimmune diseases
    Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.

Primary Outcome Measure

Systemic Lupus Erythematosus primary outcome [ Time Frame: From enrollment to the end of treatment at 24 weeks ]

Central Contacts

Related Studies